Diamond Biotechnology Co., Ltd (TPEX:6815)
15.45
+6.49 (72.39%)
At close: Nov 20, 2026
Diamond Biotechnology Revenue
Diamond Biotechnology had revenue of 280.74M TWD in the half year ending June 30, 2026, a decrease of -27.60%. This brings the company's total for the last twelve months to 464.63M, down -33.45% year-over-year. In the year 2025, Diamond Biotechnology had annual revenue of 501.49M, down -34.72%. That makes Diamond Biotechnology the 35,768th largest company in the world by revenue and 1,860th in Taiwan.
Revenue (ttm)
464.63M
Revenue Growth
-33.45%
P/S Ratio
1.32
Revenue / Employee
n/a
Employees
n/a
Market Cap
613.44M
Revenue by Geography
- Taiwan 434.23M 86.6%
- Mainland China 67.27M 13.4%
Fiscal year ended Dec 31, 2025 See the full Diamond Biotechnology breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 501.49M | -266.76M | -34.72% |
| Dec 31, 2024 | 768.25M | 152.16M | 24.70% |
| Dec 31, 2023 | 616.10M | 181.25M | 41.68% |
| Dec 31, 2022 | 434.84M | 39.64M | 10.03% |
| Dec 31, 2021 | 395.20M | 88.81M | 28.99% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Rossmax International | 3.82B |
| Cowealth Medical Holding | 2.95B |
| Radiant Innovation | 417.97M |
| Health & Life | 388.28M |
| Wiltrom | 314.12M |
| S&S Healthcare Holding | 185.52M |
| PlexBio | 137.57M |
| AmCad BioMed | 26.16M |